SPARN has developed a number of guidelines, protocols and pathways to support clinicians with the care of a patient with a rheumatological condition. Additional guidelines are being developed in 2025/26. Please check back soon for updates.
| SPARN Guidelines | Review date |
|---|---|
| Bisphosphonate protocol | 08/2028 |
| Chickenpox pathway | 03/2028 |
| ‘COVID digits’ | 03/2025 |
| Initial Diagnosis of Macrophage Activation Syndrome | 03/2025 |
| Flu statement | 03/2025 |
| Iloprost Guideline | 06/2025 |
| CNO Guideline | 05/2025 |
| Infliximab Guideline | 06/2025 |
| Kawasaki Guideline | 07/2027 |
| Methotrexate Guideline | 07/2027 |
| Methylprednisolone guideline | 06/2028 |
| NSAIDs Guideline | 07/2026 |
| Rituximab guideline | 06/2028 |
| Scleroderma Guideline | 07/2027 |
| Use of Janus kinase inhibitors | 01/2028 |
_________________
| External Guidelines |
|---|
| BSR – Guidance Management Symptomatic Hypermobility |
| WHO – Guidance for the Management of Chronic Pain in Children |
| NICE – Vitamin D deficiency in children Guideline |
_________________
| Pathways & Resources |
|---|
| Checklist for clinical guideline development |
| SPARN Standard for Paediatric Rheumatology Clinics |
| Raynaud’s Advice sheet |
| Raynaud’s holiday advice |
| https://www.nn.nhs.scot/sparn/wp-content/uploads/sites/18/2024/10/Network-JI-Request-form-v1.doc |
| Joint Injection Request Proforma |
| Referral Pathway for Children with Joint Hypermobility |
| Standards of care for children and young people with JIA |